^
    Back
    Association details:
    Biomarker:MITF amplification
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer Discov
    Title:

    The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

    Excerpt:
    Acquired MITF amplification confers resistance to MAP kinase pathway inhibition…(A) Focal genomic amplification of MITF occurs in a post-relapse sample in the absence of additional, known resistance mechanisms.
    DOI:
    10.1158/2159-8290.CD-13-0617